相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
P. Dubsky et al.
ANNALS OF ONCOLOGY (2013)
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
P. E. Goss et al.
ANNALS OF ONCOLOGY (2013)
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W. Eiermann et al.
ANNALS OF ONCOLOGY (2013)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer
J. A. Davidson et al.
EUROPEAN JOURNAL OF CANCER (2013)
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Shelby D. Reed et al.
GENETICS IN MEDICINE (2013)
Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study
G. Buckland et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
C. A. Drukker et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Aron Goldhirsch et al.
LANCET (2013)
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
Viviana Galimberti et al.
LANCET ONCOLOGY (2013)
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
Xavier Pivot et al.
LANCET ONCOLOGY (2013)
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Matthew J. Ellis et al.
CANCER DISCOVERY (2013)
Locoregional recurrence risk after lipofilling in breast cancer patients
J. Y. Petit et al.
ANNALS OF ONCOLOGY (2012)
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
A. Prat et al.
ANNALS OF ONCOLOGY (2012)
Axillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer 15-Year Results of a Randomized Controlled Trial
Gabriele Martelli et al.
ANNALS OF SURGERY (2012)
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
Malek B. Hannouf et al.
BMC CANCER (2012)
Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND)
Oreste Gentilini et al.
BREAST (2012)
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Elisabeth Luporsi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?
Viviana Galimberti et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Economic evaluation of the 70-gene prognosis-signature (MammaPrintA®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
Masahide Kondo et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
Nathan W. D. Lamond et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis
Saroj Niraula et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer
Ana P. Kiess et al.
CANCER (2012)
p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer
James G. Jackson et al.
CANCER CELL (2012)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Nasim Mavaddat et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2012)
Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
Marianne Ewertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!
Daniel F. Hayes
JOURNAL OF CLINICAL ONCOLOGY (2012)
Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer
Elizabeth J. Folkerd et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer
Michael J. Hassett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Economic Evaluation of Genomic Test-Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer
Peter S. Hall et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Estrogen receptor prevents p53-dependent apoptosis in breast cancer
Shannon T. Bailey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting
J. U. Blohmer et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis A Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
TP53 Status and Response to Treatment in Breast Cancers
Mariana Varna et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Georg Pfeiler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
Eitan Amir et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
Herve Bonnefoi et al.
LANCET ONCOLOGY (2011)
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
Thordur Oskarsson et al.
NATURE MEDICINE (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Association between breast cancer subtypes and response to neoadjuvant anastrozole
Anita K. Dunbier et al.
STEROIDS (2011)
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Marieke E. Straver et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
Torsten O. Nielsen et al.
CLINICAL CANCER RESEARCH (2010)
Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle
Pamela J. Goodwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
Ivana Sestak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
Timothy J. Whelan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
Daphne T. Tsoi et al.
ONCOLOGIST (2010)
Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)
Csaba Polgar et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
Shmuel H. Klang et al.
VALUE IN HEALTH (2010)
ACCELERATED PARTIAL BREAST IRRADIATION CONSENSUS STATEMENT FROM THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO)
Benjamin D. Smith et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Hyman B. Muss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Premenopausal endocrine-responsive early breast cancer:: who receives chemotherapy?
M. M. Regan et al.
ANNALS OF ONCOLOGY (2008)
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Giuseppe Viale et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
Pratyaksha Wirapati et al.
BREAST CANCER RESEARCH (2008)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Ki-67 expression in breast carcinoma - Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker?
H Trihia et al.
CANCER (2003)
Prognostic factors in node-negative breast cancer - A review of studies with sample size more than 200 and follow-up more than 5 years
AN Mirza et al.
ANNALS OF SURGERY (2002)
分享论文
